Andrew Balo
2017
In 2017, Andrew Balo earned a total compensation of $3M as EVP, Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development at DexCom.
Compensation breakdown
| Non-Equity Incentive Plan | $389,054 |
|---|---|
| Salary | $355,300 |
| Stock Awards | $2,250,232 |
| Other | $22,325 |
| Total | $3,016,911 |
Balo received $2.3M in stock awards, accounting for 75% of the total pay in 2017.
Balo also received $389.1K in non-equity incentive plan, $355.3K in salary and $22.3K in other compensation.
Rankings
In 2017, Andrew Balo's compensation ranked 3,610th out of 14,666 executives tracked by ExecPay. In other words, Balo earned more than 75.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,610 out of 14,666 | 75th |
Division Manufacturing | 1,247 out of 5,768 | 78th |
Major group Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 162 out of 856 | 81st |
Industry group Surgical, Medical, And Dental Instruments And Supplies | 88 out of 528 | 83rd |
Industry Surgical and Medical Instruments and Apparatus | 56 out of 333 | 83rd |
Source: SEC filing on April 20, 2018.
Balo's colleagues
We found eight more compensation records of executives who worked with Andrew Balo at DexCom in 2017.
2017
Kevin Sayer
DexCom
Chief Executive Officer
2017
Quentin Blackford
DexCom
Chief Financial Officer
2017
Terrance Gregg
DexCom
Chairman
2017
Donald Abbey
DexCom
EVP, Quality and Regulatory Affairs
2017
Steven Pacelli
DexCom
EVP, Strategy and Corporate Development
2017
Richard Doubleday
DexCom
EVP, Chief Commercial Officer
2017
Kevin Sun
DexCom
Chief Financial Officer
2017
Jess Roper
DexCom